)
)
)
SFA Therapeutics is developing a first-in-class oral small-molecule platform designed to restore immune balance by re-engaging the body’s own regulatory pathways—aiming for durable disease control without chronic immune suppression. Our lead program targets the large, underserved mild-to-moderate psoriasis market, where we have generated compelling human clinical signals demonstrating strong efficacy and a favorable tolerability profile versus current oral standards of care. Built on a scalable chemistry and manufacturing approach and supported by a growing IP estate, the platform is extensible across autoimmune and inflammatory diseases, with additional programs advancing in MASH and pancreatic cancer based on standout preclinical and early human experience. We are assembling a syndicate to accelerate pivotal development and strategic partnering.
Year Founded
2016
Next catalyst (value inflection) update
FDA Phase 2 Safe to Proceed
Expected time of next catalyst update
Mar-26
City
Jenkintown
Country
United States
Company CEO or top company official
Ira Spector, CEO
Development Phase of Primary Product
Phase II
Lead Product in Development
SFA-002 in mild to moderate psoriasis
Number of Unlicensed Products
3
Therapeutic Area
Immunology
Website
https://www.sfatherapeutics.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
